Deva To Tap Oncology Market

Turkish pharmaceutical company Deva Holding is to invest TRY60mn (US$41mn) over the next three years in the construction of an oncology production plant. Deva's aim is to produce cancer treatments at substantial discount - up to 50% - against current offerings from Western manufacturers. BMI believes Deva's strategy should enable it to increase its market share in Turkey, while also increasing its exposure in foreign

To read the full article, please choose one of the following options: